
Meghmani Organics Gears Up for Q3 Reveal on 31st January; Check Key Expectations Here
Updated: 30 Jan 2026 • 7:01 pm
Posted by:

Click and Sign Up to Get Live Updates on Q3 Results
Meghmani Organics’s Q3 results FY26 are scheduled to be announced on 31st January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.
Meghmani Organics Q3 Results 2026 Preview
- Meghmani Organics’s revenue is expected to be in the range of ₹73.44 crore, a 71.64% YoY increase.
- Profit After Tax, or PAT, is projected to fall by 52.61% YoY.
- Net profit is ₹8.77 crore, up 52.61% YoY
- EBITDA to rise 119.77%
Meghmani Organics Share Performance
- Over the past six months, Meghmani Organics’s share price has fallen by 8.95% to ₹28.00.
- Moreover, over the past year, the stock has increased by 12.87%.
- Despite this weak short-term performance, Meghmani Organics’s stock has delivered a financially sound 239.85% return over the past 5 years.
- As of 31st January 2026, the stock traded at ₹28.00 per share.
Key Factors to Watch for Meghmani Organics Q3 Results FY26
- Revenue & Segment Growth: Whether overall sales improve, especially in Crop Protection and Pigments, reflecting demand recovery and improved product mix.
- Profitability & Margins: Trends in EBITDA and net profit margins, considering recent margin compression and reliance on non‑operating income in prior quarters.
- Impact of TiO₂ Anti‑Dumping Duty: Improvement in Titanium Dioxide (TiO₂) realisations and utilisation as anti‑dumping duty takes effect, potentially lifting segment performance.
- Crop Nutrition / Nano Urea Traction: Update on Nano Urea and crop nutrition product adoption, new registrations or field trials in domestic and export markets.
Final Thoughts
Meghmani Organics will announce its Q3 FY26 results on 31st January 2026. Analysts expect 71.64% YoY revenue growth, a 88.68 rise in PAT, and a 168.58% fall in EBITDA. Meghmani Organics focuses on manufacturing and marketing crop protection chemicals, pigments, and speciality chemicals, including innovative solutions such as Nano Urea, catering to the agriculture and industrial sectors.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Recent Articles
Capital Small Finance Bank Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Carborundum Universal Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Capri Global Capital Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Digitide Solutions Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Flair Writing Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
GHCL Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Apar Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Apollo Pipes Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Recent Articles

LT Foods Q4 FY26 Results: PAT of Rs 135.67 crore Basmati Rice and Food Products
15 May 2026

Muthoot Finance Q4 FY26 Results: PAT of Rs 10,607 (FY26 consolidated annual) crore (up 98% Yo Gold Loan NBFC
15 May 2026

Alivus Life Sciences Q4 FY26 Results: Announced May 14 2026 Pharma API and CDMO – Formerly Glenmark Life Sciences
15 May 2026

Chalet Hotels Q4 FY26 Results: Announced May 14 2026 Luxury and Business Hotels
15 May 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
LT Foods Q4 FY26 Results: PAT of Rs 135.67 crore Basmati Rice and Food Products
Muthoot Finance Q4 FY26 Results: PAT of Rs 10,607 (FY26 consolidated annual) crore (up 98% Yo Gold Loan NBFC
Alivus Life Sciences Q4 FY26 Results: Announced May 14 2026 Pharma API and CDMO – Formerly Glenmark Life Sciences
Chalet Hotels Q4 FY26 Results: Announced May 14 2026 Luxury and Business Hotels
Tata Motors Passenger Vehicles Q4 FY26 Results: PAT of Rs 2,406 (standalone Tata Motors) crore (up 69.55% Yo Passenger Vehicles and EV
Popular this week
LT Foods Q4 FY26 Results: PAT of Rs 135.67 crore Basmati Rice and Food Products
Muthoot Finance Q4 FY26 Results: PAT of Rs 10,607 (FY26 consolidated annual) crore (up 98% Yo Gold Loan NBFC
Alivus Life Sciences Q4 FY26 Results: Announced May 14 2026 Pharma API and CDMO – Formerly Glenmark Life Sciences
Chalet Hotels Q4 FY26 Results: Announced May 14 2026 Luxury and Business Hotels
Tata Motors Passenger Vehicles Q4 FY26 Results: PAT of Rs 2,406 (standalone Tata Motors) crore (up 69.55% Yo Passenger Vehicles and EV

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas





